(OTC: LXXGF / TSX.V: LXG)
Major innovations in rapid pathogen detection may hold the key to halting epidemics before they spread. Take a look at the companies leading the revolution…
Thousands of times per day, patients live by a doctor’s best decision. But sometimes the most routine health problems can lead to the wrong diagnosis where wait times for virus detection can potentially lead to early fatality.
That achiness and fever after a sunny vacation could be a cold or maybe something much worse such as an unknown, potentially deadly virus such as Zika.
This new unknown bug seems like another round of flu—but that’s exactly how new pandemics spread out of control so fast.
Cases like these are why you should know about the tremendous investment potential of three companies developing life-saving point-of-care diagnostic tools that put real answers in doctors’ hands almost immediately.
The medical device sector has outperformed the S&P 500 by 138% in the last year. This is where to invest while the trend is still hot.
Thermo-Fisher Scientific (TMO), Bio-Rad (BIO) and LexaGene (TSX.V: LXG or OTC: LXXGF)—those are the names that you need to know.
That’s because these three companies make the most advanced bioassay devices on the market. Devices that correctly identify diseases by their genetic codes.
Learn More About LXXGF at your brokerage today!
There’s no doubt that TMO’s TaqMan system is the gold standard for gene-based assays. These lab-based systems rely on highly-trained technicians. When the situation calls for large numbers of samples at once—like a busy hospital—TMO is the market leader.
BIO’s competing gene-based systems are also giants meant for lab use by highly trained technicians.
But we think the greatest upside for investors is with LexaGene.
The Unmatchable LexaGene Advantage on the Front Lines
LexaGene is the newcomer, developing a fast, portable system that has set out to corner the market exactly where the two giants aren’t in charge.
LexaGene’s LX6 aims to have the same accuracy as the big systems—bioassays that are so sensitive and accurate that they can detect bacterial and viral diseases even in low, just-exposed, concentrations… even before the patient’s body has created any antibodies.
That’s why health officials can use systems like the LX6 (and the big TaqMan machines) to stop pandemics early[i]. Medical officers call them RT PCR systems—which means they are based on genetic codes. Doctors call them lifesavers because they can reliably and rapidly identify the exact virus, bacteria, or pathogen responsible for their patients’ symptoms.
And for doctors on the front line, treating patients in their own offices, the LX6 will mean answers in about an hour—no delays waiting for lab results to come back. Reducing the potential for misdiagnosis.
The LX6 is so exciting, the award-winning science show, “Innovations with Ed Begley Jr” gave LexaGene a long feature last August.
Look Where Else LexaGene Can Go
You won’t see a TaqMan in the back room at the local pediatrician’s office. Too big, too expensive. But LexaGene’s LX6 has a place there. And that’s not the only market LXG expects to win…
Veterinarians—A $4.2 billion market
Vets send out almost all their lab work. Then owners wait days to weeks for answers as their pet gets sicker. It’s not unusual for a beloved animal to die before lab results can tell the vet what to treat. Now, with an affordable LX6, vets can tell within one hour—right in their own offices—whether your dog, cat, bird or hamster has sepsis from a wound, distemper, tick-borne disease, leptospirosis or something else.
Food Safety –A $13.6 billion market
Demand for reliable food and water safety testing is at an all-time high. Reuters reports an alarming figure, “Roughly 48 million people, one in six U.S. residents, are sickened by tainted food each year and nearly 3,000 die.” Billions of dollars in lost revenue are at stake, as food producers and food chains fall victim to outbreaks of E. Coli, Salmonella, and other harmful pathogens.
You’re certain to remember Chipotle’s (NYSE: CMG) catastrophic devaluation at the height of its popularity. Chipotle lost $6 Billion in value in a matter of months, as dangerous food-borne pathogens left more than 500 patrons seriously ill. Chipotle’s stock dropped from over $750 to $420 as it reported Norovirus in California and Massachusetts, Salmonella in Minnesota, and E. Coli in a total of 9 different states.
One thing is clear, the age of Big Agriculture has brought us big sickness. Last year, US consumers suffered repeatedly from large-scale distributions of tainted food.
The foods came from trusted giants like Sargento, Hunt’s, Hostess Twinkies, and Aunt Jemima. Even healthy-seeming fresh apples and bagged salads carried listeria and salmonella. Papayas and fresh cheeses were often tainted.[ii]
Global testing for food safety is a nearly $13 billion market[iii], and still these outbreaks happen.
This is exactly where Lexagene shines. The LX6 is able to check for up to 22 different potential contaminants in less than an hour, making it economical to use in real-time at food production plants – preventing the outbreak at the source – and reducing the number of deadly food recalls that we see each year.
From the moment the first person shows up at a local hospital or clinic with suspicious symptoms, the doctor can immediately pinpoint the problem and prescribe the right treatment. Food recalls can happen fast when diagnosis is instant and correct.
Water Quality—A $3.5 billion market and Aquatic Pathogens—a $3 billion market
Locals check for e. coli, possibly giardia when there’s a question about our drinking and swimming water.
But they can easily miss other possibilities. In one short hour, LexaGene’s LX6 can check for 2 species of vibrio, 3 species of salmonella, 4 species of shigella, and 2 species of e. coli.
LexaGene—A Small Company with World-Class Credentials
LexaGene’s patented microfluidic system was invented by company founder and CEO, Dr. Jack Regan, who was a lead scientist in developing a predecessor instrument designed for bio-warfare surveillance that was adopted by the Department of Homeland Security for the BioWatch Program. He also helped develop a second R&D instrument to detect respiratory pathogens from nasal swab samples.
10 Compelling Reasons That LexaGene (TSV.V: LXG or OTC: LXXGF)
Should Be the Biggest Med-Tech Surprise of 2018
- Blue-Chip Pedigree— The technology behind the LX6 started as a Homeland Security research project with Lawrence Livermore scientists aboard, including LexaGene’s CEO. Livermore has 60 years of excellence behind it and has originated numerous defenses in scientific breakthroughs from particle accelerators to artificial retinas. Only the best scientists get to work here.
- Locked-in Patents—A better device is maximally profitable when the company that develops it has a lock on the technology, protection against cheap copycats. CEO Jack Reagan holds the three key patents that make the LX6 unique. In particular, he has control of the cartridge system that makes it possible to run the LX6 for multiple diagnostics at low costs that clinics, doctors, municipal health offices and other point-of-care practitioners will be able to afford.
- Blazing Speed—Most tests for pathogens take 3 to 5 days to get results. Lexagene’s LX6 can return assays in about an hour.
- Imminent Species Jump Potential—The worst flu pandemics on record—HIV, SARS, Ebola, even Swing and Avian flus came about when a virus jumped species. When that happens, outbreaks occur for diseases that we have never developed antibodies to fight. And in early days, they have the ability to spread rapidly out of control. Viruses constantly mutate and it’s just a matter of time before it happens again. But the LX6 can be rapidly reconfigured to test for new viruses at the earliest possible moment.
- Anti Antibiotic Overprescribing —Children often get antibiotics before tests are back because pediatricians want to start healing them as fast as possible. Cattle and chickens in the food supply are routinely dosed. The result—deadlier than ever, antibiotic-resistant strains evolve as weak germs are killed and strong ones multiply. Scientists and doctors now agree this needs to stop. The CDC has warned this practice is creating “nightmare bacteria.[iv]” LexaGene’s LX6 can test for antibiotic resistant bacteria and viruses.
- Easy Deployment—Similar systems from Thermo Fisher and BioRad are excellent. But they don’t deploy to a small doctor’s practice, the vet clinic or the places where LexaGene is aiming to provide gold-standard results with the point-of-care, affordable LX6. And best of all, operating it does not require weeks of training, it’s push-button easy for any worker, anywhere versus the need for a microbiologist.
- Open access—Most med-tech companies make their machinery so they won’t accept supplies from anyone else. And that can make purchasing officers think twice. But LexaGene is committed to an open platform that will allow reagents and standard pathogen-specific assays from other sources to make this the most affordable, customizable, and budget friendly option available.
- Earliest Detection—Results in less than an hour are one great thing about the LX6, but correctly diagnosing a virus or bacterial disease before it has a chance to spread is even better. Older systems rely on antibodies in the blood or high concentrations of pathogens. The LX6 identifies the problem genetically. It can work before antibodies even form, on tiny concentrations.
- Brilliant team—This is a scientist-led company that draws on talent recruited from top universities with substantial experience at the CDC, NIH, Qiagen, BioRad, Applied Biosystems, and Roche, to drop a few names.
- Target sales date and market opportunity—The company has stated that it is targeting LX6 beta instruments to begin shipping to beta clients by the end of 2018 and commercialization in 2019. That’s the event that will send shares soaring. With a market opportunity of over $40 billion USD, this could make LexaGene investors small fortunes in the future.
Put LexaGene on Your Radar Today
LexaGene (TSX.V: LXG or OTC: LXXGF) should be a the top of your watch list right now if you want to ride the stock market’s hot med-tech sector with the company most likely to break out of the pack.
It’s only a matter of time before the market takes note of this newcomer aiming to challenge the biggest companies in the business.
And don’t forget—there’s always the potential we haven’t even mentioned yet. A buyout from one of the BIG biotech companies because the LX6 could fill in an entirely new niche for big companies like BioRad and Thermo Fisher. And that’s just too good of an opportunity to miss.
Learn More About LXXGF at your brokerage today!
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.